$CGON

CG Oncology (NASDAQ: CGON) reported Q2 2026 results for the quarter ended June 30, 2026, with net loss of $79.1 million, or $0.90 per share. Cash, cash equivalents and marketable securities were about $1.0 billion, funding operations through 2029. The company said PIVOT-006 topline data are expected soon, and a BLA for HR BCG-unresponsive NMIBC is expected in Q4 2026.

CG Oncology, Inc. (CGON) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 3 ck0001991792-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates • PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipa

Mulay James sold 24,165 shares of CG Oncology, Inc. (CGON) at $75.16 ($1.82M total) on 2026-07-10 under a Rule 10b5-1 trading plan.

TipRanks highlights two stocks with large recent insider purchases. CG Oncology (CGON): board member Brian Guan-Chyun Liu bought 371,085 shares (~$24.8M) on June 25; company has ~$1.1B cash and expects BLA submission in 4Q26. JPMorgan rates CGON Overweight with $96 target. Adobe (ADBE): director David Ricks bought 10,000 shares (~$1.95M) on June 25 amid a shift to a freemium model.

Liu Brian Guan-Chyun purchased 371,085 indirectly-held shares of CG Oncology, Inc. (CGON) at $66.87 ($24.81M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

CG Oncology, Inc. (CGON) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001991792 0001991792 2026-06-04 2026-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2

POST LEONARD E sold 1,000 shares of CG Oncology, Inc. (CGON) at $54.50 on 2026-06-04 under a Rule 10b5-1 trading plan.

CG Oncology (CGON) is expected to report its Q1 2026 earnings before market open on Thursday, May 7th, with analysts forecasting ($0.58) EPS and $0.453 million in revenue. The company's earnings call is scheduled for May 8th at 12:30 PM ET. Insider transactions show Director James Mulay sold 15,600 shares, reducing his position by 50%, while analysts presently rate the stock a "Moderate Buy" with an average price target of $79.55.

James Mulay, a director at CG Oncology, Inc., sold 15,600 shares of company stock for $1.14 million after acquiring them through exercising director stock options. This transaction, executed under a pre-arranged Rule 10b5-1 trading plan, leaves Mulay with no direct common stock in the company. The sale occurred while the stock was near its 52-week high and followed a significant 256% gain over the past year, with analysts adjusting price targets for CG Oncology due to positive developments and trial data anticipation.

CG Oncology, Inc. has appointed Jim DeTore as its new Chief Financial Officer, effective April 13, 2026, after he served as interim principal financial officer since November 2025. DeTore will receive an annual base salary of $520,000, a target annual bonus of 45% of his salary, and equity awards including stock options with a target value of $4 million and performance stock units with a target value of $1 million. The employment agreement also outlines severance protections in case of termination, including enhanced benefits if termination occurs during a change in control.